Welcome to our dedicated page for Avadel Pharmaceu SEC filings (Ticker: AVDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avadel Pharmaceuticals plc (Nasdaq: AVDL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. Avadel is an Ireland-incorporated biopharmaceutical company focused on sleep-related disorders, and its filings provide detailed information on its commercial product LUMRYZ, clinical programs, licensing arrangements and corporate transactions.
Investors can review Avadel’s Form 10-K annual reports and Form 10-Q quarterly reports for narrative and quantitative discussions of LUMRYZ net product revenue, patient uptake, research and development spending, and risk factors related to narcolepsy, idiopathic hypersomnia and broader business operations. Current reports on Form 8-K highlight material events such as the Transaction Agreement and subsequent amendment with Alkermes plc, the proposed court-sanctioned scheme of arrangement under Irish law, settlement and license agreements with Jazz Pharmaceuticals, and the exclusive global license for valiloxybate from XWPharma.
These filings also document key clinical and regulatory milestones, including the FDA approvals that made LUMRYZ the first and only once-at-bedtime oxybate for extended-release oral suspension for cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy, Orphan Drug Exclusivity grants, and the design and status of Phase 3 studies such as REST-ON and REVITALYZ. Transaction-related disclosures describe the structure, consideration and conditions of the proposed acquisition by Alkermes and the evaluation of alternative proposals under the Irish Takeover Rules.
On Stock Titan, each new AVDL filing from EDGAR is surfaced in real time and paired with AI-powered summaries that explain the main points in clear language. Users can quickly see which filings involve LUMRYZ clinical data, royalty and license agreements, or the Alkermes acquisition terms, and can drill down into the full text for deeper analysis. Insider ownership and compensation details, when disclosed in proxy materials and related documents, are also accessible through the SEC filings stream, helping investors build a comprehensive view of governance and incentives at Avadel.
Avadel Pharmaceuticals plc filed post-effective amendments to multiple previously effective shelf registration statements to remove from registration all of its securities that remained unsold. These amendments follow the completion of a court-sanctioned scheme of arrangement under Irish law through which Alkermes plc acquired Avadel on February 12, 2026, making Avadel a wholly owned subsidiary of Alkermes.
With the transaction consummated and Avadel no longer operating as an independent public issuer, the company has terminated all offerings under its Form S-3 and Form F-3 registration statements and formally ended their effectiveness.
Avadel Pharmaceuticals plc has filed post-effective amendments to several Form S-3 and Form F-3 registration statements to deregister all securities that remained unsold under those shelves. This step follows the completion of a court-sanctioned scheme of arrangement under Irish law, through which Alkermes plc acquired Avadel.
As a result of this acquisition, Avadel became a wholly owned subsidiary of Alkermes and has terminated all offerings of its securities under the affected registration statements. The amendments formally remove any unsold securities from registration and terminate the effectiveness of those shelf registrations.
Avadel Pharmaceuticals plc filed post-effective amendments to several shelf registration statements to deregister all securities that remained unsold. This step follows the completion of a transaction under which Alkermes plc acquired Avadel through a court-sanctioned scheme of arrangement in Ireland.
As a result of the scheme, Avadel became a wholly owned subsidiary of Alkermes and terminated all offerings under the affected Form S-3 and Form F-3 registration statements. The company is formally ending the effectiveness of these registrations in line with prior undertakings to remove any unsold securities once offerings ceased.
Avadel Pharmaceuticals plc filed post-effective amendments to several shelf registration statements to deregister all securities that were never sold under those filings. This step follows completion of a court-sanctioned scheme of arrangement under Irish law through which Alkermes plc acquired Avadel.
As a result of the scheme, Avadel became a wholly owned subsidiary of Alkermes and terminated all offerings of its securities under the affected Form S-3 and Form F-3 registration statements. The amendments formally remove any remaining unsold securities from registration and terminate the effectiveness of those registration statements.
Brandes Investment Partners, L.P., a Delaware investment adviser, reports beneficial ownership of 218,835 common shares of Avadel Pharmaceuticals plc, equal to 0.22% of the class as of December 31, 2025. All voting and dispositive power over these shares is reported as shared, with no sole authority.
The filing is made on a passive Schedule 13G basis, with Brandes certifying that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Avadel.
Avadel Pharmaceuticals plc has had its ordinary shares targeted for removal from listing and/or registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq filed Form 25, certifying compliance with its rules for striking this class of securities from listing.
Avadel Pharmaceuticals plc has been acquired by Alkermes plc and is going private. Through an Irish court-sanctioned scheme of arrangement, Alkermes acquired all outstanding Avadel ordinary shares, other than those it already held, and Avadel became a wholly owned subsidiary of Alkermes.
Each Avadel shareholder as of 11:59 p.m. New York City time on February 11, 2026 is entitled to receive $21.00 in cash plus one non-transferable contingent value right per share, which may pay an additional $1.50 in cash per share upon achievement of a specified milestone. In connection with the acquisition, Avadel prepaid approximately $60,246,950 to RTW Royalty II DAC to terminate existing royalty obligations and also terminated its at-the-market equity offering program.
Trading in Avadel shares on Nasdaq has been halted and the company has requested delisting and deregistration, after which it will suspend Exchange Act reporting. At the effective time, Avadel’s executive officers and directors resigned, and its governing documents were amended as agreed in the transaction.
Avadel Pharmaceuticals plc received an amended Schedule 13G/A from investment entities associated with Jeffrey L. Gendell, reporting a reduced ownership position below the 5% threshold. This amendment is described as an exit filing for the reporting persons.
Mr. Gendell reports beneficial ownership of 4,839,357 American Depositary Shares, or 4.9% of Avadel’s ordinary shares outstanding. Within this total, Tontine Capital Overseas Master Fund II, L.P. and Tontine Asset Associates, LLC each report beneficial ownership of 2,859,475 American Depositary Shares, or approximately 2.9% of the outstanding ordinary shares.
Avadel Pharmaceuticals director Mark Anthony McCamish reported an internal share transfer involving 67,025 ordinary shares on February 4, 2026. The filing shows 67,025 shares moved from Matthew 5 LLC to the McCamish Charitable Remainder Trust at a stated price of $0 per share.
Following these transactions, 67,025 ordinary shares are reported as indirectly held through the McCamish Charitable Remainder Trust and 22,000 ordinary shares are reported as directly held. The reporting person and his spouse are income beneficiaries of the charitable remainder trust, and he disclaims beneficial ownership except for his and his spouse's pecuniary interest.
Avadel Pharmaceuticals plc reports that the High Court of Ireland has scheduled a sanction hearing on February 10, 2026 at 11:00 a.m. (Irish time) to consider the scheme of arrangement under which Alkermes plc will acquire all issued and to be issued ordinary shares of Avadel. Any interested party wishing to appear at the hearing must notify Avadel’s solicitors and, where applicable, file and serve supporting affidavits by 5:30 p.m. (Irish time) on February 5, 2026. The company states that the acquisition is expected to close shortly after the Court issues an order sanctioning the scheme, subject to satisfaction or waiver of remaining conditions and other customary risks outlined in detailed forward‑looking and Irish Takeover Rules disclosures.